Webinar: Immunomonitoring with TCR sequencing in autoimmunity

T-cells can play a crucial role in autoimmune disease development. E.g. type 1 diabetes is driven by T cells attacking insulin-producing beta cells in the pancreas. Yet most clinical trials in T1D still rely on metabolic endpoints, potentially missing important immune signals.

TCR sequencing gives you direct access to the T cell response. This webinar shows you how to turn that data into actionable immune signals for autoimmune immunotherapy development: tracking antigen-specific T cell populations, detecting repertoire shifts under treatment, and identifying biomarkers that correlate with clinical outcomes.

You will learn:

• How to design an immunomonitoring strategy around TCR sequencing for autoimmune trials
• How DETECT predicts TCR epitope specificity (including a set of T1D-relevant antigens)
• Bringing this all together on a T1D use case

This session is for clinical scientists, translational researchers, and biomarker leads at pharma and biotech companies working on autoimmune therapies like T1D.

Two time slots on 29 July 2026: 16:00-17:00 CEST and 20:00-21:00 CEST.